Related Experiment Video
Updated: Jul 18, 2026
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Emerging concepts in non-invasive monitoring of Crohn's disease
Wojciech Marlicz1, Karolina Skonieczna-Żydecka2, Konstantinos John Dabos3
1Department of Gastroenterology, Pomeranian Medical University, Unii Lubelskiej 1, 71-252 Szczecin, Poland.
Insights
New biomarkers for inflammatory bowel disease (IBD), including Crohn's disease (CD), are crucial for accurate diagnosis and monitoring. Emerging non-invasive tools like metabolomics show promise for improved patient management and prognosis.
Area of Science:
- Gastroenterology
- Biomarker Discovery
- Molecular Medicine
Background:
- Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), presents complex clinical management challenges.
- Current clinical and endoscopic scoring systems for disease monitoring and prognosis have limitations.
- There is a growing need for novel biomarkers to aid in CD diagnosis, monitoring, and prognosis.
Purpose of the Study:
- To review emerging non-invasive biomarker concepts for monitoring Crohn's disease activity and prognosis.
- To highlight the potential of metabolomics as a tool for differential IBD diagnosis.
- To discuss future developments in prognostic tools for CD management.
Main Methods:
- Review of current literature on novel biomarker concepts in IBD.
- Discussion of emerging fields including metabolomics, stem cell pathways, and microbial/metabolomic pathways.
- Exploration of cell-derived microvesicles (MVs) as potential biomarkers.
Main Results:
- Biochemical peptides are increasingly used as surrogate markers for gut inflammation in IBD.
- Metabolomics offers a powerful new approach for differential diagnosis in IBD.
- Cell-derived microvesicles (MVs) represent an emerging concept for IBD patient management.
Conclusions:
- Novel non-invasive biomarkers are essential for improving the monitoring and prognosis of Crohn's disease.
- Advancements in understanding molecular, stem cell, microbial, and metabolomic pathways are key to developing new CD biomarkers.
- Future developments in prognostic tools are expected to significantly enhance the management of CD patients.
Abstract:
Inflammatory bowel disease (IBD) is an umbrella term for Crohn's disease (CD) and ulcerative colitis (UC). In light of evolving epidemiology of CD, its clinical management is still complex and remains a challenge for contemporary physicians. With the advent of new diagnostic and treatment paradigms, there is a growing need for new biomarkers to guide decision-making, differential diagnosis, disease activity monitoring, as well as prognosis. However, both clinical and endoscopic scoring systems, widely utilized for disease monitoring and prognosis, have drawbacks and limitations. In recent years, biochemical peptides have become available for IBD monitoring and more frequently used as surrogate markers of gut inflammation. Emerging concepts that revolve around molecular, stem cell, epigenetic, microbial or metabolomic pathways associated with vascular and epithelial gut barrier could lead to development of new CD biomarkers. Measurement of cell-derived microvesicles (MVs) in the blood of IBD patients is another emerging concept helpful in future disease management. In this review, we discuss novel concepts of non-invasive biomarkers, which may become useful in monitoring of CD activity and prognosis. We discuss metabolomics as a new powerful tool for clinicians to guide differential IBD diagnosis. In the coming years, new developments of prognostic tools are expected, aiming for breakthroughs in the management of patients with CD.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:26Inflammatory Bowel Disease I: Introduction
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:20Inflammatory Bowel Disease IV: Clinical Manifestations